Tirzepatide vs Metformin
Written by Aaron CuhaReviewed Sep 2026
The short answer
A drug that copies two gut hormones, against the oldest first choice diabetes drug. Cost, how you take it and the size of the effect all differ by more than tenfold, one way or the other. And metformin has something tirzepatide does not have yet, which is decades of safety data across whole populations.
- Tirzepatide people
- 22,802
- Tirzepatide nulls
- 0
- Metformin people
- 489
- Metformin nulls
- 0
Dose
Approved titration: 2.5, 5, 7.5, 10, 12.5 and 15 mg
2.5, 5, 7.5, 10, 12.5 and 15 mg
The approved tirzepatide ladder, in mg.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone.
Column B
MetforminMetformin hydrochloride (biguanide)
A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Side by side, on the facts we can check
| What we compare | Tirzepatide | Metformin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea) | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. |
| Half-life | ~5 days | 4 to 9 hours (plasma), longer in erythrocytes |
| Molecular weight | 4,813.5 Da | 129.2 Da (165.6 Da as hydrochloride) |
| How it works | It switches on two receptors at once, GIP and GLP-1. Both answer gut hormones after a meal. Together they make the body release insulin when blood sugar is high, hold back glucagon, slow how fast the stomach empties and turn down hunger. The GIP part is thought to add its own effect on how the body handles sugar and fat. | It blocks part of the energy machinery in mitochondria, called complex I, and switches on AMPK, a fuel sensor. That makes the liver release less sugar and helps the body respond to insulin. The AMPK story is not the whole answer. Research groups still argue over how much comes from complex I, from another enzyme called mitochondrial glycerophosphate dehydrogenase, and from effects in the gut. |
| Studies in people | 11 | 7 |
| Evidence | Strong: 9 completed trials, 22,802 people given it | Moderate: 3 completed trials, 489 people given it |
| Legal status, US | FDA-approved, prescription only | Prescription only; approved for type 2 diabetes |
Frequently asked questions
What is the difference between Tirzepatide and Metformin?
Tirzepatide: A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone. Metformin: A cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Which has stronger research evidence, Tirzepatide or Metformin?
Each compound gets a band worked out from facts we counted, with the math shown. Tirzepatide is Strong (9 completed trials, 22,802 people given it). Metformin is Moderate (3 completed trials, 489 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Tirzepatide and Metformin FDA-approved?
Tirzepatide: FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea). Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity..
Related posts
Blog articles that cover Tirzepatide or Metformin, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 27, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.